Colombara Danny V, Manhart Lisa E, Carter Joseph J, Hawes Stephen E, Weiss Noel S, Hughes James P, Barnett Matt J, Goodman Gary E, Smith Jennifer S, Qiao You-Lin, Galloway Denise A
Institute for Health Metrics and Evaluation, University of Washington, 2301 Fifth Ave., Suite 600, Seattle, WA, 98121, USA.
Department of Epidemiology, School of Public Health, University of Washington, 1959 NE Pacific Street, Health Sciences Building F-250, Box 357236, Seattle, WA, 98195-7236, USA.
Cancer Causes Control. 2015 Dec;26(12):1835-44. doi: 10.1007/s10552-015-0676-3. Epub 2015 Sep 28.
To test whether infection with select human polyomaviruses (HPyV) and human papillomaviruses (HPV) is associated with incident lung cancer.
We performed a nested case-control study, testing serum from the carotene and retinol efficacy trial, conducted 1985-2005, for antibodies to Merkel cell (MCV), KI (KIV), and WU (WUV) HPyVs as well as to six high-risk and two low-risk HPV types. Incident lung cancer cases (n = 200) were frequency-matched with controls (n = 200) on age, enrollment and blood draw dates, intervention arm assignment, and the number of serum freeze/thaw cycles. Sera were tested using multiplex liquid bead microarray antibody assays. We used logistic regression to assess the association between HPyV and HPV antibodies and lung cancer.
There was no evidence of a positive association between levels of MCV, KIV, or WUV antibodies and incident lung cancer (p corrected >0.10 for all trend tests; odds ratio (OR) range 0.72-1.09, p corrected >0.10 for all). There was also no evidence for a positive association between HPV 16 or 18 infection and incident lung cancer (p corrected ≥0.10 for all trend tests; OR range 0.25-2.54, p > 0.05 for all OR > 1), but the number of persons with serologic evidence of these infections was small.
Prior infection with any of several types of HPyV or HPV was not associated with subsequent diagnosis of lung cancer. Infection with these viruses likely does not influence a person's risk of lung cancer in Western smoking populations.
检测特定人类多瘤病毒（HPyV）和人乳头瘤病毒（HPV）感染是否与肺癌发病相关。
我们进行了一项巢式病例对照研究，检测了1985年至2005年开展的胡萝卜素和视黄醇功效试验中的血清，以检测针对默克尔细胞（MCV）、KI（KIV）和WU（WUV）HPyV以及六种高危和两种低危HPV类型的抗体。肺癌发病病例（n = 200）在年龄、入组和采血日期、干预组分配以及血清冻融循环次数方面与对照组（n = 200）进行频率匹配。使用多重液滴微阵列抗体检测法对血清进行检测。我们使用逻辑回归来评估HPyV和HPV抗体与肺癌之间的关联。
没有证据表明MCV、KIV或WUV抗体水平与肺癌发病之间存在正相关（所有趋势检验的校正p值>0.10；优势比（OR）范围为0.72 - 1.09，所有校正p值>0.10）。也没有证据表明HPV 16或18感染与肺癌发病之间存在正相关（所有趋势检验的校正p值≥0.10；OR范围为0.25 - 2.54，所有OR>1时p>0.05），但有这些感染血清学证据的人数较少。
先前感染几种类型的HPyV或HPV中的任何一种与随后的肺癌诊断无关。在西方吸烟人群中，感染这些病毒可能不会影响一个人患肺癌的风险。
